Overview

Peter L’Ecluse focuses on life sciences, competition law and intellectual property (IP) rights.

Life Sciences

Peter’s expertise encompasses a wide range of areas, including registration, pricing and reimbursement matters, advertising issues and all aspects of competition law. He has successfully represented clients before civil courts, as well as Belgium’s administrative court, the Council of State, in challenging reimbursement decisions and rules imposing prescription requirements on physicians.    

Competition Law

Peter has been involved in most of the significant cases arising before the Belgian competition authorities and the courts. His expertise in this area extends to merger control, dominant market positions and procedural issues. 

Peter has extensive experience in the patent licensing area and is currently advising patent owners in two distinct cases pending before German courts.

IP Rights

Peter’s patent litigation practice focuses on the life sciences industry. For several years, he has acted as co-counsel for one of the largest pharmaceutical companies in the world, handling multi-jurisdictional patent litigation while defending valuable patents covering various active substances against generic competitors. Peter also acted as co-counsel in proceedings before the European Patent Office and the Belgian courts for a major medical devices company in patent litigation which covered three jurisdictions. He often advises on supplementary protection certificate patent extension issues and assists clients in dealing with counterfeit trade in pharmaceuticals.

Languages

Dutch, English, French

Recommendations

  • Best Lawyer – Lawyer of the Year for Biotechnology and Life Sciences 2020
  • Chambers Europe – Competition: Domestic
  • Chambers Europe for Intellectual Property
  • Chambers Europe – ‘Leaders In Their Field’ (Competition: Domestic)
  • Chambers Europe – ‘Leaders In Their Field’ (Intellectual Property) 
  • IAM Patent 1000 – The World’s Leading Patent Practitioners
  • Managing Intellectual Property – IP Star
  • LMG Life Sciences (Europe) – Life Sciences Star 
  • PLC for Belgium Life Sciences – Regulatory
  • PLC for Belgium Life Sciences – Intellectual Property
  • PLC for Europe Life Sciences – Competition/Anti-trust
  • PLC for Belgian Competition Law/Anti-trust
  • PLC for Belgium Dispute Resolution
  • International Who’s Who Legal for Life Sciences
  • Legal 500 for Intellectual Property
  • Legal 500 for Dispute Resolution 
  • Legal 500 for EU Regulatory – Pharma and Biotech
  • European Legal Experts for Intellectual Property
  • World IP Review – WIPR Leader

Education

  • The George Washington University, Washington DC, Master of Comparative Law, 1987
  • University of Leuven (KUL), Master of Laws, 1986
  • University of Leuven (KUL), Baccalaureus of Philosophy, 1985

Publications

Widely published on issues involving life sciences and competition law.

Contributor to Van Bael & Bellis' Business Law Guide to Belgium (Kluwer Law International/Bruylant, 2003).

Contributor to “Private Antitrust Litigation” (European Lawyer Reference/Thomson Reuters, 2013).

Contributor to Van Bael & Bellis, Competition Law of the European Community (fifth edition, Kluwer, 2010), the standard work of reference in the field of EU competition law.

Bar Admission

Brussels
Former member of the Bar Council of Dutch language lawyers (Brussels)

Publications and insights

Sign up for updates
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more
    • 02/07/2020
    • Articles

    Healthcare Priorities of German Presidency of EU Council

    The German government assumed yesterday for the latter part of 2020 the rotating Presidency of the Council of the European Union. The policy priorities of that Presidency were spelled out in the attached document entitled “Together for Europe’s recovery”. Not surprisingly, healthcare forms a focal point of these priorities in a number of diverging ways:

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *